Sign In
Buy SDZNY
$79.34
-0.468 (-0.586%)
At Close: Jun 03, 2026
Sandoz Group AG (SDZNY) Q2 2024 Earnings Call Transcript
10:52am, Thursday, 08'th Aug 2024
Sandoz Group AG (OTCQX:SDZNY) Q2 2024 Earnings Conference Call August 8, 2024 3:00 AM ET Company Participants Karen King - Global Head, Investor Relations Richard Saynor - Chief Executive Officer Remc
Sandoz reports second-quarter sales and half-year 2024 results
01:00am, Thursday, 08'th Aug 2024
Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules MEDIA RELEASE Strong double-digit growth in biosimilars of 29% from existing portfolio and recent launches Second-quarter net s
Sandoz launches biosimilar Pyzchiva® (ustekinumab) across Europe, to treat chronic inflammatory diseases
01:00am, Thursday, 25'th Jul 2024
Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules Sandoz launches biosimilar Pyzchiva® (ustekinumab) across Europe, to treat chronic inflammatory diseases Launch across Europe,
3 Spinoff Stocks You Should Buy Now: July 2024
12:31pm, Monday, 15'th Jul 2024
Stock spinoffs remain popular with companies wanting to unlock shareholder value. By creating spinoff stocks that will trade independently on the market, corporations believe they can narrow their f
Just - Evotec Biologics Expands Tech Partnership for Biosimilars with Sandoz
08:20am, Monday, 08'th Jul 2024
Just - Evotec Biologics expands partnership with Sandoz for development and commercial manufacturing of biosimilars Additional biosimilars potentially to be added to Sandoz development pipeline Furthe
FDA approves biosimilar Pyzchiva® (ustekinumab-ttwe), to be commercialized by Sandoz in US
01:00am, Monday, 01'st Jul 2024
Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules FDA approves biosimilar Pyzchiva® (ustekinumab-ttwe), to be commercialized by Sandoz in US Pyzchiva® (ustekinumab-ttwe) is ap
Sandoz receives European Commission approval for Wyost® and Jubbonti®, the first and only biosimilars of denosumab in Europe
01:00am, Wednesday, 22'nd May 2024
Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules MEDIA RELEASE Wyost® (denosumab) and Jubbonti® (denosumab) approved by EC for all indications of denosumab reference medicine
Sandoz reports first quarter 2024 sales
01:00am, Tuesday, 07'th May 2024
Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules MEDIA RELEASE Strong first quarter performance, with net sales [1] of USD 2.5 billion, up 6% in constant currencies (up 5% in
Shareholders approve all resolutions proposed by Board of Directors at Annual General Meeting of Sandoz Group AG
06:25am, Tuesday, 30'th Apr 2024
All proposals of Board of Directors approved Gilbert Ghostine re-elected as Chairman of Board of Directors; all other Board members standing for election confirmed Mathai Mammen, Graeme Pitkethly and
Sandoz reaches agreement with Amgen over patent dispute
01:51am, Tuesday, 30'th Apr 2024
Swiss generic and biosimilar manufacturer Sandoz said on Tuesday it had reached an agreement with U.S. drugmaker Amgen resolving all patent litigation related to its U.S. denosumab biosimilars.
Sandoz reaches agreement with Amgen resolving all patent litigation related to its US denosumab biosimilars
01:00am, Tuesday, 30'th Apr 2024
Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules Sandoz reaches agreement with Amgen resolving all patent litigation related to its US denosumab biosimilars Agreement clears pa
Sandoz confirms European Commission approval of Pyzchiva® (ustekinumab), further strengthening immunology offering
01:00am, Monday, 22'nd Apr 2024
Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules Pyzchiva® approved as one of first ustekinumab biosimilars in Europe EC approval based on robust development program confirmin
Sandoz opens new antibiotic production facility in Austria, to significantly increase capacity for life-saving medicines
09:00am, Thursday, 21'st Mar 2024
MEDIA RELEASE EUR 50m investment in Kundl plant extension emphasizes commitment to serve more patients with critical antibiotics, produced entirely in Europe Additional manufacturing area of 3,000m2 m
Sandoz reports fourth quarter 2023 sales and full-year 2023 results
02:00am, Wednesday, 13'th Mar 2024
Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules MEDIA RELEASE Strong fourth quarter performance, with net sales1 of USD 2.5 billion, up 10% in constant currencies (up 11% in U
Sandoz receives FDA approval for first and only denosumab biosimilars
01:24pm, Tuesday, 05'th Mar 2024
MEDIA RELEASE Wyost® (denosumab-bddz) and Jubbonti® (denosumab-bddz) interchangeable with and approved by FDA for all indications of reference medicines Xgeva ®* (denosumab) and Prolia®* (denosuma
